Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT02869568
Recruiting Observational

Institut Paoli Calmettes Ovarian Cancer Database

NCT02869568 · tracked via the Priya Life Science France tracker
Sponsor
Institut Paoli-Calmettes
Phase
Observational
Started
2000-01
Last updated
2016-08-17

Condition(s) studied

Ovarian Neoplasms

Investigational drug(s) / intervention(s)

Data collection

Study summary

Database of Institut Paoli-Calmettes patients diagnosed with ovarian cancer

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
95 Years
Healthy volunteers
No
Inclusion Criteria: * Patient with a diagnosis of ovarian cancer Exclusion Criteria: * Diagnosis of fallopian tube cancer

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Institut Paoli-Calmettes Marseille Bouches-du Rhône Recruiting

More Institut Paoli-Calmettes trials in France

Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma Recruiting
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Recruiting
Pancreatic Surgical Database Recruiting
Evaluation of the Use of a Biodegradable Endoprothesis in the Prevention of Post-Endoscopic Retrograde CholoangioPancreatography Pancreatitis Recruiting
Institut Paoli Calmettes Multiple Myeloma Database Recruiting

Other trials for the same condition

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Recruiting
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Active, not recruiting
Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02869568 on ClinicalTrials.gov ↗ ← All trials in France